勒沃西门丹的外科应用优化了严重心力衰竭患者的术后功能和器官输血
Vasileios Leivaditis1, Manfred Dahm1, Anastasia Papaporfyriou2
1Department of Cardiothoracic and Vascular Surgery, Westpfalz-Klinikum, 67655 Kaiserslautern, Germany.
Journal of cardiovascular development and disease
|July 28, 2023
概括
莱沃西门丹治疗显著改善了功能,并减少了心脏手术患者需要替代疗法的需要. 这种无otropic药物还增强了器官输液,并减少了手术后的炎症.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏手术带来功能障碍和器官输液受损的风险.
- 患有低射出率和严重心肌功能障碍的患者特别容易受到伤害.
- 莱沃西门丹是一种具有潜在益处的内类药物,在这个高危人群中具有潜在的益处.
研究的目的:
- 评估levosimendan在改善术后功能方面的疗效.
- 评估levosimendan对心脏手术后器官输液的影响.
- 为了确定levosimendan是否减少了对脏替代疗法的需要.
主要方法:
- 对314名手术前心力衰竭患者进行心脏手术的回顾性分析.
- 184名接受外科手术期间治疗的患者和130名接受常规治疗的患者之间的比较.
- 分析功能标志物,器官输液指标和炎症标志物.
主要成果:
- 莱沃西门丹显著降低了对脏替代疗法的需要 (p < 0.001).
- 观察到血清肌素,淋巴膜过率和肌素清除的改善.
- 观察到器官 perfusion 的增强和降低 C-反应蛋白水平.
结论:
- 在外科手术期间使用levosimendan可改善高风险心脏手术患者的术后功能.
- 莱沃西门丹治疗与脏替代疗法的需求降低有关.
- 该药物还减轻了器官输出失调,并减少了手术后的炎症反应.
相关概念视频
01:22Heart Failure Drugs: Diuretics
422
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
422
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
16
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
16
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:26Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16